Pfizer is training pharmacists in the U.K. to handle over-the-counter Viagra.

The problems at a Celltrion plant that threaten Teva's fremanezumab launch may be less limited than the company had hoped, analysts say.

AstraZeneca's Imfinzi won't have its first-line lung cancer data till later than expected, and at a time when Merck's Keytruda is racing ahead.

Gilead released data from a clinical trial showing that its new three-med HIV combo Biktarvy is noninferior to a treatment containing three GSK drugs.

Look at the last 20 years' worth of drug launches and one thing is clear: Hep C fueled some NASA-worthy blastoffs. But they're not the only ones.

With an early approval for its new drug Erleada, J&J just got a head start over Pfizer and Astellas in nonmetastatic prostate cancer.

CEO Vas Narasimhan has said Novartis' Advair generic—specifically its approval this year—was one of his top three worries. That worry just grew.

Amid a Street-beating Q4 report, GlaxoSmithKline quantified the hit it’s been bracing for: Advair generics. Short answer? Half its U.S. sales.